Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Posted: October 30, 2024 at 2:42 am

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology -

Read more:
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Related Posts